These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2992350)

  • 1. Studies on the conformation, enzymatic degradation, pharmacological potency, and binding properties in brain tissue of cholecystokinin-8 and new related peptides.
    Roques BP; Durieux C; Gacel G; Pélaprat D; Ruiz-Gayo M; Belleney J; Fellion E; Zajac JM; Fournié-Zaluski MC; Daugé V
    Ann N Y Acad Sci; 1985; 448():61-75. PubMed ID: 2992350
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of [3H]cholecystokinin octapeptide binding to mouse brain synaptosomes: effects of neuroleptics.
    Hama Y; Ebadi M
    Neurochem Res; 1987 Aug; 12(8):729-37. PubMed ID: 3627361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of central and peripheral cholecystokinin receptors by new glutaramic acid derivatives with cholecystokinin-antagonistic activity.
    Makovec F; Bani M; Chisté R; Revel L; Rovati LC; Rovati LA
    Arzneimittelforschung; 1986; 36(1):98-102. PubMed ID: 3006713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the role of "enkephalinase" in cholecystokinin inactivation.
    Zuzel KA; Rose C; Schwartz JC
    Neuroscience; 1985 May; 15(1):149-58. PubMed ID: 3892359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic degradation of cholecystokinin in the central nervous system.
    Deschodt-Lanckman M
    Ann N Y Acad Sci; 1985; 448():87-98. PubMed ID: 3896101
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence for a high-affinity uptake system for cholecystokinin octapeptide (CCK8) in rat cortical synaptosomes.
    Migaud M; Roques BP; Durieux C
    Eur J Neurosci; 1995 May; 7(5):1074-9. PubMed ID: 7613612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholecystokinin turnover in brain.
    Meek JL; Iadarola MJ; Giorgi O
    Brain Res; 1983 Oct; 276(2):375-8. PubMed ID: 6313133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photoaffinity labeling of central cholecystokinin receptors with high efficiency.
    Thiele C; Fahrenholz F
    Biochemistry; 1993 Mar; 32(11):2741-6. PubMed ID: 8457542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of brain penetration of CCK-B antagonists.
    Dubroeucq MC; Guyon C; Manfré F; Capet M; Barreau M; Bertrand P; Jeantaud B; Doble A; Blanchard JC
    Ann N Y Acad Sci; 1994 Mar; 713():377-9. PubMed ID: 8185193
    [No Abstract]   [Full Text] [Related]  

  • 11. Cholecystokinin octapeptide: vesicular localization and calcium dependent release from rat brain in vitro.
    Emson PC; Lee CM; Rehfeld JF
    Life Sci; 1980 Jun; 26(25):2157-63. PubMed ID: 6249988
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of sulfate ester in influencing biologic activity of cholecystokinin-related peptides.
    Vinayek R; Jensen RT; Gardner JD
    Am J Physiol; 1987 Feb; 252(2 Pt 1):G178-81. PubMed ID: 2435164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
    Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
    J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New proglumide-analogue CCK receptor antagonists: very potent and selective for peripheral tissues.
    Niederau C; Niederau M; Williams JA; Grendell JH
    Am J Physiol; 1986 Jun; 250(6 Pt 1):G856-60. PubMed ID: 2424321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in cholecystokinin receptor binding in rat brain after food deprivation.
    Finkelstein JA; Steggles AW; Martinez P; Praissman M
    Brain Res; 1983 Dec; 288(1-2):193-7. PubMed ID: 6318886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin-dopamine receptor interactions as studied with cholecystokinin receptor antagonists.
    Murphy RB
    Prog Clin Biol Res; 1985; 192():105-13. PubMed ID: 3001746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a serine peptidase responsible for the inactivation of endogenous cholecystokinin in human brain.
    Rose C; Vargas F; Silhouette B; Devaux B; Schwartz JC
    Neuropeptides; 1995 Mar; 28(3):157-60. PubMed ID: 7791959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological evaluation of JMV180 cholecystokinin analogs.
    Amblard M; Lignon MF; Bernad N; Noel-Artis AM; Hauad L; Laur J; Rodriguez M; Galas MC; Fourmy D; Martinez J
    Ann N Y Acad Sci; 1994 Mar; 713():79-87. PubMed ID: 7514377
    [No Abstract]   [Full Text] [Related]  

  • 19. Discrimination between CCK receptors of guinea-pig and rat brain by cyclic CCK8 analogues.
    Durieux C; Pham H; Charpentier B; Roques BP
    Biochem Biophys Res Commun; 1988 Aug; 154(3):1301-7. PubMed ID: 3408499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on the radioligand binding assay of cholecystokinin receptor in rat cerebral cortex].
    Xiang P; Chen M; Tan T; Shi Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1999 Jun; 30(2):214-6, 221. PubMed ID: 12212064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.